{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:09:35Z","timestamp":1790615375952,"version":"4.1.0"},"reference-count":25,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Aripiprazole is a first-line agent in the treatment of bipolar disorder (BD) and available data demonstrates its efficacy on clinical symptoms in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder (OCD) patients. Therefore, aripiprazole augmentation to mood stabilizers could represent a promising treatment in BD patients with comorbid OCD. The study examined the efficacy and safety of aripiprazole added to lithium or valproate for the treatment of obsessive-compulsive (OC) symptoms in euthymic BD patients with comorbid OCD. Materials and Methods: This is a 12-week prospective observational study. The efficacy of aripiprazole on OC symptoms was assessed through the mean change of Yale\u2013Brown Obsessive-Compulsive (YBOCS) total score. Tolerability was assessed with the Utvalg for Kliniske Undersogelser (UKU) side effect scale and by reporting adverse events. Results: A total of 70 patients were included in the analyses. The withdrawal rate was 21.4%, mainly due to adverse events. Mean \u00b1 SD final aripiprazole dose was 15.2 \u00b1 5.3 in the completer sample (N = 55). The Y-BOCS mean score decreased from 24.0 \u00b1 4.1 at baseline to 17.1 \u00b1 4.3 at 12 weeks. Treatment response rate (Y-BOCS reduction \u2265 35%) was 41.8%, while partial response rate (Y-BOCS reduction greater than 25% but less than 35% from baseline) accounted for the other 18.2% of patients. Overall, 91.4% of completers had at least 1 adverse effect (tremor, tension\/inner unrest, reduced duration of sleep, akathisia). No significant differences emerged comparing aripiprazole efficacy and tolerability between patients treated with lithium or valproate. Conclusion: Our findings show that aripiprazole addition to lithium or valproate can reduce OC symptoms in real-world BD euthymic patients.<\/jats:p>","DOI":"10.3390\/medicina57010009","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T09:02:44Z","timestamp":1608800564000},"page":"9","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder"],"prefix":"10.3390","volume":"57","author":[{"given":"Gabriele","family":"Di Salvo","sequence":"first","affiliation":[{"name":"Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[{"name":"Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"},{"name":"Psychiatric Unit, San Luigi Gonzaga University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pessina","sequence":"additional","affiliation":[{"name":"Mental Health Department of Alba and Bra, 12042 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Teobaldi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"},{"name":"Psychiatric Unit, San Luigi Gonzaga University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barbaro","sequence":"additional","affiliation":[{"name":"Mental Health Department of Alba and Bra, 12042 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzurra","family":"Martini","sequence":"additional","affiliation":[{"name":"Mental Health Department of Alba and Bra, 12042 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Albert","sequence":"additional","affiliation":[{"name":"Psychiatric Section, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Rosso","sequence":"additional","affiliation":[{"name":"Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"},{"name":"Psychiatric Unit, San Luigi Gonzaga University Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-1781(95)02752-1","article-title":"Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders","volume":"59","author":"Chen","year":"1995","journal-title":"Psychiatry Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000077740","article-title":"The sesto fiorentino study: Background, methods and preliminary results. Lifetime prevalence of psychiatric disorders in an Italian community sample using clinical interviewers","volume":"73","author":"Faravelli","year":"2004","journal-title":"Psychother. Psychosom."},{"key":"ref_4","first-page":"10","article-title":"The comorbidity of anxiety disorders in bipolar I patients: Prevalence and clinical correlates","volume":"43","author":"Altindag","year":"2006","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jad.2017.08.012","article-title":"Exploration of comorbid obsessive-compulsive disorder in patients with bipolar disorder: The clinic-based prevalence rate, symptoms nature and clinical correlates","volume":"225","author":"Jeon","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_6","first-page":"353","article-title":"Correlates and impact of obsessive compulsive comorbidity in bipolar disorder","volume":"51","author":"Kapczinski","year":"2009","journal-title":"Compr. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jad.2014.12.019","article-title":"Comorbid obsessive compulsive disorder in patients with bipolar-I disorder","volume":"174","author":"Shashidhara","year":"2015","journal-title":"J. Affect. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00406-006-0658-2","article-title":"Comorbidity of anxiety disorders in patients with remitted bipolar disorder","volume":"256","author":"Zutshi","year":"2006","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113088","DOI":"10.1016\/j.psychres.2020.113088","article-title":"Impact of comorbid obsessive-compulsive disorder on suicidality in patients with bipolar disorder","volume":"290","author":"Pessina","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/0019-5545.192001","article-title":"Management of obsessive-compulsive disorder comorbid with bipolar disorder","volume":"58","author":"Kazhungil","year":"2016","journal-title":"Indian J. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/0019-5545.99543","article-title":"Antidepressant-induced mania in obsessive compulsive disorder","volume":"54","author":"Philip","year":"2012","journal-title":"Indian J. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1399-5618.2004.00109.x","article-title":"Clinical management of obsessive-compulsive-bipolar comorbidity: A case series","volume":"6","author":"Raja","year":"2004","journal-title":"Bipolar Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4088\/JCP.v69n0413","article-title":"Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: A randomized, single-blind, pilot study","volume":"69","author":"Maina","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"ref_14","first-page":"e562","article-title":"The treatment of adult bipolar disorder with aripiprazole: A systematic review","volume":"8","author":"Muneer","year":"2016","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0004867415617657","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders","volume":"49","author":"Malhi","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.2174\/0929867325666171222163645","article-title":"A systematic review of evidence-based treatment strategies for obsessive- compulsive disorder resistant to first-line pharmacotherapy","volume":"25","author":"Albert","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","article-title":"Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study","volume":"31","author":"Muscatello","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/YIC.0b013e32832e9b91","article-title":"Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A 12-week open-label preliminary study","volume":"24","author":"Pessina","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","article-title":"Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial)","volume":"29","author":"Sayyah","year":"2012","journal-title":"Depress. Anxiety"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pnpbp.2018.03.014","article-title":"Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial","volume":"84","author":"Sahraian","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/wps.20299","article-title":"Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder","volume":"15","author":"Nordsletten","year":"2016","journal-title":"World Psychiatry"},{"key":"ref_23","first-page":"8","article-title":"Efficacy and safety of aripiprazole in the treatment of bipolar disorder: A systematic review","volume":"27","author":"Fountoulakis","year":"2009","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-5618.2011.00898.x","article-title":"Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: A multicenter, double-blind, randomized study","volume":"13","author":"Marcus","year":"2011","journal-title":"Bipolar Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:45:46Z","timestamp":1760179546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["medicina57010009"],"URL":"https:\/\/doi.org\/10.3390\/medicina57010009","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,24]]}}}